Harmaline ameliorating role against liver cirrhosis via hepatic arginase-I activity modulation

Document Type : Original Article

Authors

1 Assistant professor of biochemistry, Faculty of Science, Damanhour University

2 Biochemistry Division, Chemistry Department, Faculty of Science, Damanhour University, Egypt.

3 Prof. of Biochemistry, Faculty of Science. Tanta University

4 biochemistry, faculty of science , tanta university

Abstract

Liver cirrhosis, the 11th most common cause of death, is a severe disease that includes inflammation, oxidative damage, also immune response. Harmaline shows the antioxidant and anti-inflammatory mechanisms that aid in partial protection of hepatic cirrhosis.

Objective: This work aimed to evaluate the protection effect of harmaline against liver cirrhosis induced by thioacetamide in mice via arginase-1 enzyme activity modulation.

Methods: The study was carried out on forty male mice divided into four groups. Control group (GI), thioacetamide group (GII), harmaline group (GIII), and co-treated group (GIV). By the end of the experiment, arginase-1 activity and liver enzymes were measured in serum and liver tissue.
Results: The results showed that combined harmaline administration can cause significant suppression of liver inflammation by increasing ariginase-1 activity to nearly normal values. Inhibition of hepatic stellate cell activation and extracellular matrix deposition were also noticed.

Conclusion: Harmaline has protective role against liver cirrhosis induced by thioacetamide in mice. It can be therapeutically used as a safe liver support after further in vivo studies.

Keywords

Biochemistry Letters

Articles in Press, Accepted Manuscript
Available Online from 06 March 2021

Files

Share

How to cite

Statistics